



BAC  
PHE

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

TECH CENTER 1600/2900

SEP 24 2001

RECEIVED

Applicants: Stefan Dietmar Anker and Andrew Justin Stewart Coats

Serial No.: 09/807,558 Art Unit: 1614

Filed: July 17, 2001 Examiner: Not Yet Assigned

For: *METHODS OF TREATMENT*

Assistant Commissioner for Patents  
Washington, D.C. 20231

**INFORMATION DISCLOSURE STATEMENT**

Sir:

Pursuant to 37 C.F.R. §1.56 and 37 C.F.R. §1.97, Applicants submit an Information Disclosure Statement, including eight (8) pages of Form PTO-1449 and a copy of each document cited therein.

This Information Disclosure Statement is being filed under 37 C.F.R. § 1.97(b) prior to a first Office Action on the merits. It is believed that no fee is required with this submission. However, should a fee be required, the Commissioner is hereby authorized to charge any required fees to Deposit Account No. 50-1868.

**Foreign Documents**

<u>Number</u>	<u>Publication Date</u>	<u>Patentee</u>	<u>Country</u>
WO 96/24373 A2	08-15-1996	G.D. Searle & Co.	PCT
09 071 586	03-18-1997	Yamanouchi Oharm Co.	JP

**Publications**

ANKER & COATS, "Cardiac Cachexia. A syndrome with impaired survival and immune and neuroendocrine activation," *Chest* 115:836-847 (1999).

ANKER & RAUCHHAUS, "Insights into the pathogenesis of chronic heart failure: immune activation and cachexia," *Curr Opin Cardiol* 14(3):211-216 (1999).

ANKER, "Catecholamine levels and treatment in chronic heart failure," *Eur. Heart J.* 19(Suppl F.):56-61 (1998).

ANKER, "Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure," *Heart* 78:39-43 (1997).

ANKER, et al., "Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure," *European Heart Journal* 20:683-693 (1999).

ANKER, et al., "Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia," *Circulation* 96:526-534 (1998).

ANKER, et al., "Loss of bone mineral in patients with cachexia due to chronic heart failure," *Am J Cardiol* 83:612-615 (1999).

ANKER, et al., "The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure," *European Heart Journal* 18:259-269 (1997).

ANKER, et al., "Tumor necrosis factor and steroid metabolism in chronic heart failure: Possible relation to muscle wasting," *J Amer Coll Cardiol* 30:997-1001 (1997).

ANKER, et al., "Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure," *Q. J. Med.* 91:199-203 (1998).

BENEDICT & GRAHAME-SMITH, "Plasma adrenaline and noradrenaline concentrations and dopamine- $\beta$ -hydroxylase activity in myocardial infarction with and without cardiogenic shock," *British Heart Journal* 42:214-220 (1979).

BERNE, "Effect of epinephrine and norepinephrine on coronary circulation," *Circ Res* 6:644-655 (1958).

BESARB, et al., "The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin," *N Eng J Med* 339(9):584-590 (1998).

BRINK, et al., "Angiotension II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism," *J Clin Invest* 97(11):2509-2516 (1996).

U.S.S.N.: 09/807,558

Filed: July 17, 2001

INFORMATION DISCLOSURE STATEMENT

CHILAIN, et al., "Adrenergic coronary tone during submaximal exercise in the dog is produced by circulating catecholamines," *Cir Res* 58:68-82 (1986).

CHUA, et al., "Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure," *J Am Coll Cardiol* 27:650-657 (1996).

COATS, "Symptoms and quality of life in heart failure: the muscle hypothesis," "Symptoms and quality of life in heart failure: the muscle hypothesis," *Br. Heart J* 72:S36-S39 (1994).

COWIE, et al., "The epidemiology of heart failure," *European Heart Journal* 18:208-225 (1997).

DANERYD, et al., "Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study," *Cancer Res.* 58(23):5374-5379 (1998).

DAVENPORT, "Characterization of [<sup>125</sup>I]-PD164333, an ET<sub>A</sub> selective non-peptide radiolabelled antagonists, in normal and diseased human tissues," *Br. J Pharmacol* 123(2):223-30 (1998).

DOHERTY, et al., "In vitro and in vivo studies with a series of hexapeptide endothelin antagonists," *J Cardiovascular Pharmacology* 22(Suppl 8):S98-S102 (1993).

D'USCIO, et al., "Effects of chronic ET<sub>A</sub>-receptor blockade in angiotensin II-induced hypertension," *Hypertension* 29(1 Pt. 2):435-41 (1997).

FRANCIS, "Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure," *Circulation* 82:1724-1729 (1990).

GAGNON & BRUERA, "A review of the drug treatment of cachexia associated with cancer," *Drugs* 55(5):675-688 (1998).

GOLDSTEIN, "Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology," *Am J Cardiol* 48:1147-54 (1981).

GORTER, "Management of anorexia-cachexia associated with cancer and HIV infection," *Oncology* 5(9):13-17 (1991).

GREENBAUM, et al., "Host cathepsin D response to tumor in the normal and pepstatin-treated mouse," *Cancer Res.* 43(6):2584-2587 (1983).

HARRIS, "Congestive cardiac failure: central role of the arterial blood pressure," *Br Heart J* 58:190-203 (1987).

U.S.S.N.: 09/807,558

Filed: July 17, 2001

INFORMATION DISCLOSURE STATEMENT

HASHIDA, "Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L *in vitro* and *in vivo*," *J Biochem* 88:1805-1811 (1980).

HEUSCH & DEUSSEN, "The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog," *Circ Res* 53:8-15 (1983).

HEUSCH, " $\alpha$ -Adrenergic mechanisms in myocardial ischemia," *Circulation* 81:1-13 (1990).

HUANG, et al., "Antialdosterone therapy in severe chronic congestive heart failure," *Zhonghua Xinxiueguanbing Zazhi* 24(1):12-15 (1996).

IHARA, et al., "In vitro biological profile of a highly potent novel endolethial (ET) antagonist BQ-123 selective for the ET<sub>A</sub> receptor," *J Cardiovasc Pharmacol* 20(Suppl. 12):S11-S14 (1992).

ISHIKAWA, et al., "Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788," *Proc Natl Acad Sci USA* 91:4892-4892 (1994).

JAE, et al., "Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ET<sub>A</sub>/ET<sub>B</sub> mixed antagonists," *J Med Chem* 40:3217-3227 (1997).

KALIMI, et al., "Effects of antimineralcorticoid RU 26752 on steroid-induced hypertension in rats," *Am J Physiol* 258(5, Pt 1):E737-9 (1990).

KICHUK, et al., "Angiotension-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts," *Am J Cardiol* 80:137A-142A (1997).

KIM, et al., "Evaluation of RU28318 and RU40555 as selective mineralocorticoid receptor and glucocorticoid receptor antagonists, respectively: receptor measures and functional studies," *J Steroid Biochem Mol Biol* 67(3):213-22 (1998).

LEY, et al., "Sex- and menopause-associated changes in body-fat distribution," *Am J Clin Nutr* 55:950-4 (1992).

LEZA, et al., *Revista de Farmacologia Clinica y Experimental* 4/4:377-383 (1987).

LIU, et al., "Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-nonyl, highly selective ET<sub>A</sub> antagonist (A-261546)," *J Med Chem* 41:3261-3275 (1998).

MAGUIRE, et al., "Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET<sub>A</sub> and ET<sub>B</sub> receptors," *J Pharmacol Exp Ther* 280(2):1102-8 (1997).

U.S.S.N.: 09/807,558

Filed: July 17, 2001

INFORMATION DISCLOSURE STATEMENT

MCDONALD, et al., "Plasma-catecholamines after cardiac infarction," *Lancet* 2:1021-1023 (1969).

MIHARA, et al., "Binding characterization of [<sup>3</sup>H]S-0139, an antagonist of the endothelin ET<sub>A</sub> receptor subtype," *Eur J Pharmacol* 342:2-3:319-24 (1998).

MIYATA, et al., "WS-7338, New endothelin receptor antagonists isolated from *Streptomyces* sp. No. 7338. II. Biological characterization and pharmacological characterization of WS-7338 B," *J Antibiot (Tokyo)* 45(1):83-7 (1992).

MUELLER & AYRES, "Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man," *J Clin Invest* 65:338-346 (1980).

MUELLER, et al., "Cardiac catecholamine response during evolving myocardial infarct in man," *Circulation* 62(Suppl III):III-81 (1980).

NAMBI, et al., "Nonpeptide endothelin receptor antagonists. 1. Effects on binding and signal transduction on human endothelin<sub>A</sub> and endothelin<sub>B</sub> receptors," *J Pharmacol Exp Ther* 271(2):755-61 (1994).

NYCANDER, et al., "Two-step mechanism of inhibition of cathepsin B by cystatin C due to displacement of the proteinase occluding loop," *FEBS Lett* 422:61-64 (1998).

OHSITA, et al., "Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro," *NEur J Biochem* 209(1):223-31 (1992).

PACKER, "The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure," *J Am Coll Cardiol* 20:248-254 (1992).

PIEPOLI, et al., "Contribution of muscle afferents to the hemodynamic, autonomic and ventilatory responses to exercise in patients with chronic heart failure," *Circulation* 93(5):940-952 (1996).

POMIKOWSKI, et al., "Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure," *Circulation* 96(8):2586-2594 (1997).

RAHMAN, et al., ""Angiotensin II and aldosterone have opposite effects on magnesium excretion in man," *Scot Med. J.* 37:157-158 (1992).

U.S.S.N.: 09/807,558

Filed: July 17, 2001

INFORMATION DISCLOSURE STATEMENT

REMES, "Neuroendocrine activity in untreated heart failure," *Br Heart J* 65:249-255 (1991).

ROUX, et al., "Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm," *J Pharmacol Exp Ther* 283(3):1110-18 (1997).

SAKAKI, et al., "Discovery of IRL 3461: A novel and potent endothelin antagonist with balanced ET<sub>A</sub>/ET<sub>B</sub> affinity," *Bioorg Med Chem Lett* 8(16):2241-6 (1998).

SHEN, et al., "Defective endogenous nitric oxide-mediated modulation of cellular respiration in canine skeletal muscle after the development of heart failure," *J Heart Lung Transplant* 16(10):1026-1034 (1997).

SIGGERS, et al., "Serial plasma adrenaline and noradrenaline levels in myocardial infarction using a new double isotope technique," 33:878-883 (1971).

SIGURDSSON, et al., "Short- and long-term neurohormonal activation following acute myocardial infarction," *Am Heart J* 126:1068-1076 (1993).

SUTSCH, et al., "Short-term oral endothelial-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure," *Circulation* 98(21):2262-2268 (1998).

TASKER, et al., "Potent and selective non-benzodioxole-containing endothelin-A-receptor antagonists," *J Med Chem* 40:322-330 (1997).

The SOLVD Investigators, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure," *N Eng J Med* 325:293-302 (1991).

TOWATARI, et al., "Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, *in vivo*," *N FEBS Lett* 280(2):311-5 (1991).

TSCHESCHE, "Bimolecular interaction of matrix metalloproteinases and their inhibitors," *J Protein Chem* 17(6):549-51 (1998).

TURK, et al., "Identification of bovine stefin A, a novel protein inhibitor of cysteine proteinases," *FEBS Lett* 360:101-105 (1995).

VETTER, et al., "Initial metabolic and hormonal response to acute myocardial infarction," *Lancet* 1:284-289 (1974).

WEINDEL, et al., "Inhibitory effects of the novel anti-aldosterone compound mespirenone on adrenocortical steroidogenesis in vitro," *Arzneimittelforschung* 41(9):946-9 (1991).

U.S.S.N.: 09/807,558  
Filed: July 17, 2001  
INFORMATION DISCLOSURE STATEMENT

ZHANG, et al., "ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption," *Circulation* 95(1):176-182 (1997).

### Remarks

This statement should not be interpreted as a representation that an exhaustive search has been conducted or that no better art exists. Moreover, Applicants invite the Examiner to make an independent evaluation of the cited art to determine its relevance to the subject matter of the present application. Applicants are of the opinion that their claims patentably distinguish over the art referred to herein, either alone or in combination.

Respectfully submitted,



\_\_\_\_\_  
Patrea L. Pabst  
Reg. No. 31,284

Dated: September 18, 2001


HOLLAND & KNIGHT LLP  
One Atlantic Center  
1201 West Peachtree Street, N.E.  
Suite 2000  
Atlanta, Georgia 30309-3400  
404-817-8500  
FAX 404-817-0470  
[www.hklaw.com](http://www.hklaw.com)

U.S.S.N.: 09/807,558  
Filed: July 17, 2001  
INFORMATION DISCLOSURE STATEMENT

**Certificate of Mailing under 37 C.F.R. § 1.8(a)**

I hereby certify that this Information Disclosure Statement, along with any paper referred to as being attached or enclosed, is being deposited with the United States Postal Service on the date shown below with sufficient postage as first-class mail in an envelope addressed to the Assistant Commissioner for Patents, Washington, D.C. 20231.

Date: September 18 , 2001



Kimberly L. Adams

Please type a plus sign (+) inside this box →

+

PTO/SB/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

**Substitute for form 1449A/PTO**

## **INFORMATION DISCLOSURE STATEMENT BY APPLICANT**

(use as many sheets as necessary)

1 of 8

**Complete if Known**

Application Number	09/807,558 00/2900
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ICI 102

## **U.S. PATENT DOCUMENTS**

## **FOREIGN PATENT DOCUMENTS**

Examiner Signature		Date Considered	
-----------------------	--	-----------------	--

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the grant of the European patent will suffice.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you are required to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS.

L

Please type a plus sign (+) inside this box →

PTO/SB/08A (10-03)  
Approved for use through 10/31/03. OMB 0651-003  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TECH CENTER 1600/2900  
REC'D SEP 24 2001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**

(use as many sheets as necessary)



Sheet 2 of 8

Complete if Known	
Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ICI 102

**OTHER ART – NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		ANKER & COATS, "Cardiac Cachexia. A syndrome with impaired survival and immune and neuroendocrine activation," <i>Chest</i> 115:836-847 (1999).	
		ANKER & RAUCHHAUS, "Insights into the pathogenesis of chronic heart failure: immune activation and cachexia," <i>Curr Opin Cardiol</i> 14(3):211-216 (1999).	
		ANKER, "Catecholamine levels and treatment in chronic heart failure," <i>Eur. Heart J.</i> 19(Suppl F.):56-61 (1998).	
		ANKER, "Relation between serum uric acid and lower limb blood flow in patients with chronic heart failure," <i>Heart</i> 78:39-43 (1997).	
		ANKER, et al., "Cytokines and neurohormones relating to body composition alterations in the wasting syndrome of chronic heart failure," <i>European Heart Journal</i> 20:683-693 (1999).	
		ANKER, et al., "Hormonal changes and catabolic/anabolic imbalance in chronic heart failure and their importance for cardiac cachexia," <i>Circulation</i> 96:526-534 (1998).	
		ANKER, et al., "Loss of bone mineral in patients with cachexia due to chronic heart failure," <i>Am J Cardiol</i> 83:612-615 (1999).	
		ANKER, et al., "The influence of muscle mass, strength, fatigability and blood flow on exercise capacity in cachectic and non-cachectic patients with chronic heart failure," <i>European Heart Journal</i> 18:259-269 (1997).	
		ANKER, et al., "Tumor necrosis factor and steroid metabolism in chronic heart failure: Possible relation to muscle wasting," <i>J Amer Coll Cardiol</i> 30:997-1001 (1997).	
		ANKER, et al., "Tumour necrosis factor alpha as a predictor of impaired peak leg blood flow in patients with chronic heart failure," <i>Q. J. Med.</i> 91:199-203 (1998).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →  +

PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

SEP

24

2001

RECEIVED  
EPOCH CENTER 1600/2900

INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT

(use as many sheets as necessary)

3 of 8

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ICI 102

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		BENEDICT & GRAHAME-SMITH, "Plasma adrenaline and noradrenaline concentrations and dopamine-b-hydroxylase activity in myocardial infarction with and without cardiogenic shock," <i>British Heart Journal</i> 42:214-220 (1979).	
		BERNE, "Effect of epinephrine and norepinephrine on coronary circulation," <i>Circ Res</i> 6:644-655 (1958).	
		BESARB, et al., "The effects of normal as compared with low hematocrit values in patients with cardiac disease who are receiving hemodialysis and epoetin," <i>N Eng J Med</i> 339(9):584-590 (1998).	
		BRINK, et al., "Angiotension II causes weight loss and decreases circulating insulin-like growth factor I in rats through a pressor-independent mechanism," <i>J Clin Invest</i> 97(11):2509-2516 (1996).	
		CHILAIN, et al., "Adrenergic coronary tone during submaximal exercise in the dog is produced by circulating catecholamines," <i>Cir Res</i> 58:68-82 (1986).	
		CHUA, et al., "Relation between chemosensitivity and the ventilatory response to exercise in chronic heart failure," <i>J Am Coll Cardiol</i> 27:650-657 (1996).	
		COATS, "Symptoms and quality of life in heart failure: the muscle hypothesis," "Symptoms and quality of life in heart failure: the muscle hypothesis," <i>Br. Heart J</i> 72:S36-S39 (1994).	
		COWIE, et al., "The epidemiology of heart failure," <i>European Heart Journal</i> 18:208-225 (1997).	
		DANERYD, et al., "Protection of metabolic and exercise capacity in unselected weight-losing cancer patients following treatment with recombinant erythropoietin: A randomized prospective study," <i>Cancer Res.</i> 58(23):5374-5379 (1998).	
		DAVENPORT, "Characterization of [ <sup>125</sup> I]-PD164333, an ET <sub>A</sub> selective non-peptide radiolabelled antagonists, in normal and diseased human tissues," <i>Br. J Pharmacol</i> 123(2):223-30 (1998).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE  
Approved for use through 10/31/93 OMB 0651-0031  
P-1055/08A (10-96)

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

**RECEIVED**  
**SEARCH CENTER 1600/290**  
**SEP 24 2001**

**Complete if Known**

Application Number	09/807,558				
Filing Date	July 17, 2001				
First Named Inventor	Stefan Dietmat Anker				
Group Art Unit	1614				
Examiner Name					
Sheet	4	of	8	Attorney Docket Number	ICI 102

**OTHER ART – NON PATENT LITERATURE DOCUMENTS**

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		DOHERTY, et al., "In vitro and in vivo studies with a series of hexapeptide endothelin antagonists," <i>J Cardiovascular Pharmacology</i> 22(Suppl 8):S98-S102 (1993).	
		D'USCIO, et al., "Effects of chronic ET <sub>A</sub> -receptor blockade in angiotensin II-induced hypertension," <i>Hypertension</i> 29(1 Pt. 2):435-41 (1997).	
		FRANCIS, "Comparison of neuroendocrine activation in patients with left ventricular dysfunction with and without congestive heart failure," <i>Circulation</i> 82:1724-1729 (1990).	
		GAGNON & BRUERA, "A review of the drug treatment of cachexia associated with cancer," <i>Drugs</i> 55(5):675-688 (1998).	
		GOLDSTEIN, "Plasma norepinephrine as an indicator of sympathetic neural activity in clinical cardiology," <i>Am J Cardiol</i> 48:1147-54 (1981).	
		GORTER, "Management of anorexia-cachexia associated with cancer and HIV infection," <i>Oncology</i> 5(9):13-17 (1991).	
		GREENBAUM, et al., "Host cathepsin D response to tumor in the normal and pepstatin-treated mouse," <i>Cancer Res.</i> 43(6):2584-2587 (1983).	
		HARRIS, "Congestive cardiac failure: central role of the arterial blood pressure," <i>Br Heart J</i> 58:190-203 (1987).	
		HASHIDA, "Inhibitions by E-64 derivatives of rat liver cathepsin B and cathepsin L <i>in vitro</i> and <i>in vivo</i> ," <i>J Biochem</i> 88:1805-1811 (1980).	
		HEUSCH & DEUSSEN, "The effects of cardiac sympathetic nerve stimulation on perfusion of stenotic coronary arteries in the dog," <i>Circ Res</i> 53:8-15 (1983).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

PTO/AF-08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TE  
CENTER  
600/2900

SEP 24 2001

RECEIVED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ICI 102



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

5 of 8

### OTHER ART – NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		HEUSCH, "α-Adrenergic mechanisms in myocardial ischemia," <i>Circulation</i> 81:1-13 (1990).	
		HUANG, et al., "Antialdosterone therapy in severe chronic congestive heart failure," <i>Zhonghua Xinxueguanbing Zazhi</i> 24(1):12-15 (1996).	
		IHARA, et al., "In vitro biological profile of a highly potent novel endothelial (ET) antagonist BQ-123 selective for the ET <sub>A</sub> receptor," <i>J Cardiovasc Pharmacol</i> 20(Suppl. 12):S11-S14 (1992).	
		ISHIKAWA, et al., "Biochemical and pharmacological profile of a potent and selective endothelin B-receptor antagonist, BQ-788," <i>Proc Natl Acad Sci USA</i> 91:4892-4892 (1994).	
		JAE, et al., "Pyrrolidine-3-carboxylic acids as endothelin antagonists. 2. Sulfonamide-based ET <sub>A</sub> /ET <sub>B</sub> mixed antagonists," <i>J Med Chem</i> 40:3217-3227 (1997).	
		KALIMI, et al., "Effects of antimineralcorticoid RU 26752 on steroid-induced hypertension in rats," <i>Am J Physiol</i> 258(5, Pt 1):E737-9 (1990).	
		KICHUK, et al., "Angiotension-converting enzyme inhibitors promote nitric oxide production in coronary microvessels from failing explanted human hearts," <i>Am J Cardiol</i> 80:137A-142A (1997).	
		KIM, et al., "Evaluation of RU28318 and RU40555 as selective mineralocorticoid receptor and glucocorticoid receptor antagonists, respectively: receptor measures and functional studies," <i>J Steroid Biochem Mol Biol</i> 67(3):213-22 (1998).	
		LEY, et al., "Sex- and menopause-associated changes in body-fat distribution," <i>Am J Clin Nutr</i> 55:950-4 (1992).	
		LEZA, et al., <i>Revista de Farmacología Clínica y Experimental</i> 4/4:377-383 (1987).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →  +

Approved for use through 10/31/00. OMB 0651-003  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

RECEIVED  
TECH CENTER 1600/2900  
SEP 24 2001

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ICI 102

Sheet 6 of 8

OTHER ART -- NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		LIU, et al., "Pyrrolidine-3-carboxylic acids as endothelin antagonists. 3. Discovery of a potent, 2-noraryl, highly selective ET <sub>A</sub> antagonist (A-261546)," <i>J Med Chem</i> 41:3261-3275 (1998).	
		MAGUIRE, et al., "Affinity and selectivity of PD156707, a novel nonpeptide endothelin antagonist, for human ET <sub>A</sub> and ET <sub>B</sub> receptors," <i>J Pharmacol Exp Ther</i> 280(2):1102-8 (1997).	
		MCDONALD, et al., "Plasma-catecholamines after cardiac infarction," <i>Lancet</i> 2:1021-1023 (1969).	
		MIHARA, et al., "Binding characterization of [ <sup>3</sup> H]S-0139, an antagonist of the endothelin ET <sub>A</sub> receptor subtype," <i>Eur J Pharmacol</i> 342:2-3:319-24 (1998).	
		MIYATA, et al., "WS-7338, New endothelin receptor antagonists isolated from <i>Streptomyces</i> sp. No. 7338. II. Biological characterization and pharmacological characterization of WS-7338 B," <i>J Antibiot (Tokyo)</i> 45(1):83-7 (1992).	
		MUELLER & AYRES, "Propranolol decreases sympathetic nervous activity reflected by plasma catecholamines during evolution of myocardial infarction in man," <i>J Clin Invest</i> 65:338-346 (1980).	
		MUELLER, et al., "Cardiac catecholamine response during evolving myocardial infarct in man," <i>Circulation</i> 62(Suppl III):III-81 (1980).	
		NAMBI, et al., "Nonpeptide endothelin receptor antagonists. 1. Effects on binding and signal transduction on human endothelin <sub>A</sub> and endothelin <sub>B</sub> receptors," <i>J Pharmacol Exp Ther</i> 271(2):755-61 (1994).	
		NYCANDER, et al., "Two-step mechanism of inhibition of cathepsin B by cystatin C due to displacement of the proteinase occluding loop," <i>FEBS Lett</i> 422:61-64 (1998).	
		OHSHITA, et al., "Effects of selective inhibition of cathepsin B and general inhibition of cysteine proteinases on lysosomal proteolysis in rat liver in vivo and in vitro," <i>N Eur J Biochem</i> 209(1):223-31 (1992).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →

0/SB/08A (10-03)  
Approved for use through 10/31/03 OMB 0651-0032  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

RECEIVED  
TECH CENTER 1600/2900  
SEP 24 2001

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO

Complete if Known

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ICI 102

Sheet 7 of 8

OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		PACKER, "The neurohormonal hypothesis: a theory to explain the mechanism of disease progression in heart failure," <i>J Am Coll Cardiol</i> 20:248-254 (1992).	
		PIEPOLI, et al., "Contribution of muscle afferents to the hemodynamic, autonomic and ventilatory responses to exercise in patients with chronic heart failure," <i>Circulation</i> 93(5):940-952 (1996).	
		POMIKOWSKI, et al., "Augmented peripheral chemosensitivity as a potential input to baroreflex impairment and autonomic imbalance in chronic heart failure," <i>Circulation</i> 96(8):2586-2594 (1997).	
		RAHMAN, et al., "'Angiotensin II and aldosterone have opposite effects on magnesium excretion in man," <i>Scot Med. J.</i> 37:157-158 (1992).	
		REMES, "Neuroendocrine activity in untreated heart failure," <i>Br Heart J</i> 65:249-255 (1991).	
		ROUX, et al., "Ro 61-1790, a new hydrosoluble endothelin antagonist: general pharmacology and effects on experimental cerebral vasospasm," <i>J Pharmacol Exp Ther</i> 283(3):1110-18 (1997).	
		SAKAKI, et al., "Discovery of IRL 3461: A novel and potent endothelin antagonist with balanced ET <sub>A</sub> /ET <sub>B</sub> affinity," <i>Bioorg Med Chem Lett</i> 8(16):2241-6 (1998).	
		SHEN, et al., "Defective endogenous nitric oxide-mediated modulation of cellular respiration in canine skeletal muscle after the development of heart failure," <i>J Heart Lung Transplant</i> 16(10):1026-1034 (1997).	
		SIGGERS, et al., "Serial plasma adrenaline and noradrenaline levels in myocardial infarction using a new double isotope technique," 33:878-883 (1971).	
		SIGURDSSON, et al., "Short- and long-term neurohormonal activation following acute myocardial infarction," <i>Am Heart J</i> 126:1068-1076 (1993).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+

Please type a plus sign (+) inside this box →


PTO/SB/08A (10-96)  
Approved for use through 10/31/99. OMB 0651-0031  
Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

TELEFAX CENTER 1600/2900  
24  
2001

RECEIVED

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number

Substitute for form 1449A/PTO



## INFORMATION DISCLOSURE STATEMENT BY APPLICANT

(use as many sheets as necessary)

Sheet 8 of 8

### Complete if Known

Application Number	09/807,558
Filing Date	July 17, 2001
First Named Inventor	Stefan Dietmat Anker
Group Art Unit	1614
Examiner Name	
Attorney Docket Number	ICI 102

### OTHER ART - NON PATENT LITERATURE DOCUMENTS

Examiner's Initials*	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published	T <sup>2</sup>
		SUTSCH, et al., "Short-term oral endothelial-receptor antagonist therapy in conventionally treated patients with symptomatic severe chronic heart failure," <i>Circulation</i> 98(21):2262-2268 (1998).	
		TASKER, et al., "Potent and selective non-benzodioxole-containing endothelin-A-receptor antagonists," <i>J Med Chem</i> 40:322-330 (1997).	
		The SOLVD Investigators, "Effect of enalapril on survival in patients with reduced left ventricular ejection fractions and congestive heart failure," <i>N Eng J Med</i> 325:293-302 (1991).	
		TOWATARI, et al., "Novel epoxysuccinyl peptides. A selective inhibitor of cathepsin B, <i>in vivo</i> ," <i>N. FEBS Lett</i> 280(2):311-5 (1991).	
		TSCHESCHE, "Bimolecular interaction of matrix metalloproteinases and their inhibitors," <i>J Protein Chem</i> 17(6):549-51 (1998).	
		TURK, et al., "Identification of bovine stefin A, a novel protein inhibitor of cysteine proteinases," <i>FEBS Lett</i> 360:101-105 (1995).	
		VETTER, et al., "Initial metabolic and hormonal response to acute myocardial infarction," <i>Lancet</i> 1:284-289 (1974).	
		WEINDEL, et al., "Inhibitory effects of the novel anti-aldosterone compound mespirenone on adrenocortical steroidogenesis <i>in vitro</i> ," <i>Arzneimittelforschung</i> 41(9):946-9 (1991).	
		ZHANG, et al., "ACE inhibitors promote nitric oxide accumulation to modulate myocardial oxygen consumption," <i>Circulation</i> 95(1):176-182 (1997).	

Examiner's Signature	Date Considered
----------------------	-----------------

\*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

<sup>1</sup> Unique citation designation number <sup>2</sup> See attached Kinds of U.S. Patent Documents. <sup>3</sup> Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup> For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup> Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup> Applicant to place a check mark here if English language Translation is attached.

Burden Hour Statement: This form is estimated to take 2.0 hours to complete. Time will vary depending upon the needs of the individual case. Any comments on the amount of time you require to complete this form should be sent to the Chief Information Officer, Patent and Trademark Office, Washington, DC 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. SEND TO: Assistant Commissioner for Patents, Washington, DC 20231.

+